Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial.

MLA

Jin, Shuiling, et al. “Feasibility and Tolerability of Sintilimab plus Anlotinib as the Second-Line Therapy for Patients with Advanced Biliary Tract Cancers: An Open-Label, Single-Arm, Phase II Clinical Trial.” International Journal of Cancer, vol. 152, no. 8, Apr. 2023, pp. 1648–58. EBSCOhost, https://doi.org/10.1002/ijc.34372.

APA

Jin, S., Zhao, R., Zhou, C., Zhong, Q., Shi, J., Su, C., Li, Q., Su, X., Chi, H., Lu, X., Jiang, G., Chen, R., Han, J., Jiang, M., Qiao, S., Liu, J., Song, M., Song, L., Du, Y., … Zong, H. (2023). Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. International Journal of Cancer, 152(8), 1648–1658. https://doi.org/10.1002/ijc.34372

Chicago

Jin, Shuiling, Ruihua Zhao, Chuang Zhou, Qian Zhong, Jianxiang Shi, Chang Su, Qinglong Li, et al. 2023. “Feasibility and Tolerability of Sintilimab plus Anlotinib as the Second-Line Therapy for Patients with Advanced Biliary Tract Cancers: An Open-Label, Single-Arm, Phase II Clinical Trial.” International Journal of Cancer 152 (8): 1648–58. doi:10.1002/ijc.34372.